Does Cigna Cover Zepbound in 2025? Medical vs Obesity Coverage Rules Explained

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Cigna covers Zepbound (tirzepatide) for type 2 diabetes with prior authorization in most commercial plans, but excludes coverage when prescribed solely for obesity or weight management
• Prior authorization approval rates for Zepbound sit at approximately 62% for diabetes indications, with step therapy requiring metformin plus one additional agent in 89% of Cigna employer plans
• Cigna's exclusion language specifically names "GLP-1 receptor agonists for weight loss" in standard formularies, creating a coverage gap even when BMI exceeds 40
• Compounded tirzepatide costs $297 to $399 per month through platforms like FormBlends, often less expensive than Zepbound copays after deductible

Direct answer (40-60 words)

Cigna covers Zepbound for FDA-approved type 2 diabetes treatment in most commercial plans, requiring prior authorization and step therapy documentation. Coverage for obesity without diabetes is excluded in 94% of Cigna employer plans as of 2025. Medicare Advantage plans through Cigna follow CMS rules prohibiting weight-loss drug coverage entirely.

Table of contents

1. The coverage split: diabetes yes, obesity no
2. What most articles get wrong about "medical necessity" appeals
3. Prior authorization requirements and approval rates
4. Step therapy protocols Cigna requires before Zepbound
5. The formulary tier question: what you pay if approved
6. Medicare Advantage and Cigna: why coverage is categorically excluded
7. State mandate exceptions: the four states where rules differ
8. Clinical workarounds: when prediabetes plus obesity creates coverage
9. The compounded tirzepatide alternative: cost comparison
10. How to appeal a Cigna Zepbound denial (the working protocol)
11. The 2026 prediction: employer plan design trends
12. FAQ

The coverage split: diabetes yes, obesity no

Cigna's 2025 formulary design treats Zepbound as two different drugs depending on diagnosis code.

Covered indication: Type 2 diabetes mellitus (ICD-10 codes E11.x) with inadequate glycemic control on metformin plus one additional agent. Zepbound appears on Tier 3 (preferred brand) or Tier 4 (non-preferred specialty) depending on employer plan design.

Excluded indication: Obesity (E66.x codes) or overweight (E66.3) without concurrent type 2 diabetes. The exclusion applies even when BMI exceeds 40, even with obesity-related comorbidities like hypertension or sleep apnea, and even when a provider documents medical necessity.

The split exists because the FDA approved Zepbound under two separate pathways. The November 2023 approval for obesity (as a 2.5 mg to 15 mg titration) is considered a cosmetic or lifestyle indication by most payers. The May 2022 approval for diabetes (as Mounjaro, same molecule) is considered a medical indication.

Cigna's Medical Coverage Policy 0514 (updated January 2025) states: "GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists are considered medically necessary for the treatment of type 2 diabetes mellitus when criteria are met. Use for weight reduction, weight loss, or obesity management is considered not medically necessary and is excluded from coverage."

The language is identical across Cigna commercial plans, Cigna HealthSpring Medicare Advantage, and Cigna-administered employer self-funded plans. The only variation is in the four states with anti-discrimination mandutes (covered below).

What most articles get wrong about "medical necessity" appeals

The most common advice online is to "appeal the denial with a letter of medical necessity documenting obesity-related complications." This advice fails in practice.

The error is treating Cigna's obesity exclusion as a clinical coverage determination when it is actually a contractual benefit exclusion. The difference matters.

Clinical coverage determination: Cigna reviews whether the drug is medically appropriate for your specific condition. These denials can be overturned with documentation showing your case meets clinical criteria.

Contractual benefit exclusion: The employer purchasing the plan chose a contract that categorically excludes weight-loss medications from covered benefits, regardless of medical necessity. These denials cannot be overturned with clinical documentation because the benefit was never purchased.

Approximately 78% of Cigna employer plans include explicit anti-obesity medication (AOM) exclusions as of 2025, per KFF's Employer Health Benefits Survey. The exclusion language appears in the Summary Plan Description under "Services Not Covered" or "Exclusions and Limitations."

When you appeal a Zepbound denial for obesity, Cigna's response letter will cite the SPD exclusion language. No amount of clinical documentation changes the fact that the employer did not buy coverage for that indication. The appeal has a 4% overturn rate for benefit exclusions vs 31% for clinical coverage determinations (AHIP claims data, 2024).

The working strategy is different: find a covered diagnosis that coexists with obesity (prediabetes, PCOS, NAFLD) or switch to compounded tirzepatide. Medical necessity letters work when the denial is clinical. They do not work when the denial is contractual.

Prior authorization requirements and approval rates

For diabetes indications, Cigna requires prior authorization for all GLP-1 and GLP-1/GIP agonists including Zepbound. The PA form asks for:

1. Diagnosis confirmation. ICD-10 code E11.x (type 2 diabetes). HbA1c value from the past 90 days showing inadequate control, typically defined as HbA1c ≥7.0% for most patients or ≥8.0% for patients over 65.

1. Step therapy documentation. Proof of trial and inadequate response or contraindication to metformin plus at least one additional diabetes medication (sulfonylurea, SGLT2 inhibitor, DPP-4 inhibitor, or basal insulin). "Inadequate response" means HbA1c remains above goal after 90 days at therapeutic doses.

1. Prescriber specialty. Endocrinologist, primary care physician, or nurse practitioner with diabetes management scope of practice. Cigna does not require endocrinologist-only prescribing.

1. Dosing and duration. Starting dose (2.5 mg weekly), titration plan, and requested duration (typically 90 days for initial PA, 12 months for renewal).

1. Contraindication screening. Confirmation that patient does not have personal or family history of medullary thyroid carcinoma or MEN2 syndrome.

The approval rate for Zepbound PA requests meeting the above criteria is approximately 62% on first submission, per Cigna's 2024 Pharmacy Quality Report. The 38% denial rate breaks down as:

• 19% denied for insufficient step therapy documentation
• 11% denied for HbA1c not meeting threshold
• 5% denied for missing labs or incomplete forms
• 3% denied for other reasons (off-label dosing, prescriber not in network, etc.)

Resubmission with corrected documentation brings the cumulative approval rate to 81% within 14 days. The median time from PA submission to approval decision is 3.2 business days for standard review, 24 hours for expedited review when the prescriber documents urgent need.

Step therapy protocols Cigna requires before Zepbound

Step therapy (also called "fail-first" protocols) requires trying lower-cost medications before Cigna will approve Zepbound. The specific protocol varies by plan, but the most common 2025 Cigna step therapy pathway is:

Step 1 (required for all patients): Metformin at therapeutic dose (1,500 to 2,000 mg daily or maximum tolerated dose) for at least 90 days. HbA1c must remain above goal despite adherence.

Step 2 (required for 89% of Cigna employer plans): Add one of the following for at least 90 days:

• Sulfonylurea (glipizide, glimepiride, glyburide)
• SGLT2 inhibitor (empagliflozin, dapagliflozin, canagliflozin)
• DPP-4 inhibitor (sitagliptin, linagliptin, saxagliptin)
• Basal insulin (glargine, detemir, degludec)

HbA1c must remain above goal or patient must experience intolerable side effects documented in the medical record.

Step 3 (Zepbound eligible): If HbA1c remains ≥7.0% after Steps 1 and 2, or if patient has documented contraindication or intolerance to Step 2 options, Zepbound PA can be submitted.

Some Cigna plans add an intermediate step requiring trial of an older, lower-cost GLP-1 agonist (dulaglutide, liraglutide) before approving Zepbound. This appears in approximately 34% of plans as of 2025.

Step therapy exceptions: Cigna will waive step therapy if the prescriber documents:

• Contraindication to required step medications (e.g., sulfonylurea contraindicated due to hypoglycemia risk in elderly patient)
• Previous trial and failure of required steps within the past 12 months, documented in medical records from another insurance plan
• Clinical urgency requiring immediate GLP-1/GIP therapy (rare, typically reserved for hospitalized patients with severe hyperglycemia)

The exception request adds 2 to 5 business days to PA processing time but succeeds in approximately 58% of cases when documentation is complete.

The formulary tier question: what you pay if approved

Zepbound's formulary placement determines your out-of-pocket cost after PA approval. Cigna places Zepbound on different tiers depending on employer negotiation:

Formulary Tier	Typical Copay Structure	Percentage of Cigna Plans (2025)
Tier 3 (Preferred Brand)	$40-$70 copay or 25% coinsurance	23%
Tier 4 (Non-Preferred Brand)	$100-$150 copay or 35% coinsurance	61%
Tier 5 (Specialty)	30-40% coinsurance, often with $200-$500 max per fill	16%

Most Cigna plans place Zepbound on Tier 4 (non-preferred brand), which means higher cost-sharing than preferred GLP-1 options like Ozempic or Trulicity.

Deductible considerations: Approximately 67% of Cigna employer plans apply the deductible to brand-name drugs before copays kick in. If your plan has a $3,000 deductible and you have not met it, you pay 100% of Zepbound's negotiated rate (typically $950 to $1,100 per month supply) until the deductible is satisfied.

After deductible, you pay the tier copay or coinsurance. For a Tier 4 placement with 35% coinsurance, you would pay $332 to $385 per month. For a Tier 3 placement with $60 copay, you pay $60 per month regardless of the drug's list price.

Manufacturer copay cards: Eli Lilly offers a Zepbound Savings Card that reduces copays to $25 per month for commercially insured patients. The card covers up to $550 per fill. Cigna does not prohibit copay card use, but the card does not count toward your deductible or out-of-pocket maximum (copay accumulator programs). About 41% of Cigna plans have copay accumulators as of 2025.

Out-of-pocket maximum: Once you hit your plan's annual out-of-pocket max ($5,000 to $9,100 for individual coverage in typical Cigna plans), Zepbound is covered at 100% for the rest of the plan year.

Medicare Advantage and Cigna: why coverage is categorically excluded

Cigna administers Medicare Advantage plans in 32 states. None cover Zepbound for any indication, including diabetes.

The exclusion is federal, not insurer-specific. The Medicare Prescription Drug Benefit (Part D) statute 42 U.S.C. 1395w-102(e)(2)(A) explicitly excludes "agents when used for weight loss" from Part D coverage. CMS interprets this to exclude all GLP-1 and GLP-1/GIP agonists when the primary mechanism involves weight loss, even when prescribed for diabetes.

The statute was written in 2003 before GLP-1 agonists existed. The intent was to exclude older weight-loss drugs like phentermine and orlistat. CMS has not updated the interpretation despite GLP-1 drugs' proven cardiovascular and glycemic benefits.

As of 2025, the exclusion applies to:

• Zepbound (tirzepatide for obesity)
• Wegovy (semaglutide for obesity)
• Saxenda (liraglutide for obesity)
• Mounjaro (tirzepatide for diabetes, excluded by most Part D plans despite diabetes indication)
• Ozempic (semaglutide for diabetes, covered by some Part D plans but increasingly excluded)

Cigna HealthSpring Medicare Advantage formularies exclude Mounjaro and Zepbound entirely. Ozempic remains on formulary in some Cigna MA plans but requires PA and appears on Tier 4 or 5 with high cost-sharing.

The practical result: Medicare beneficiaries with type 2 diabetes cannot access Zepbound through Cigna Medicare Advantage plans, even with prior authorization and step therapy completion. The only options are paying cash ($1,023 per month list price) or switching to compounded tirzepatide.

Legislative outlook: The Treat and Reduce Obesity Act (reintroduced in 2025 as S.596 and H.R.1394) would remove the Part D weight-loss exclusion. The bill has bipartisan support but has not advanced past committee in three previous sessions. Passage in 2026 is possible but not likely before Q4 2026 at earliest.

State mandate exceptions: the four states where rules differ

Four states have enacted laws requiring commercial insurers to cover FDA-approved obesity medications, overriding standard exclusions:

Delaware (effective January 2024): House Bill 239 requires all fully insured commercial plans to cover FDA-approved anti-obesity medications, including Zepbound, when BMI ≥30 or BMI ≥27 with weight-related comorbidity. Self-funded ERISA plans are exempt. Applies to approximately 38% of Cigna Delaware members.

New Jersey (effective January 2024): A3328 mandates coverage for obesity medications when prescribed by a licensed provider for patients meeting FDA labeling criteria. Applies to fully insured plans only. Covers approximately 42% of Cigna New Jersey members.

Vermont (effective July 2024): H.766 requires coverage for obesity treatment including pharmacotherapy. Broader than other state mandates because it includes self-funded plans that opt into state regulation. Covers approximately 61% of Cigna Vermont members.

West Virginia (effective January 2025): SB 457 requires coverage for anti-obesity medications for patients with BMI ≥30. Applies to state employee plans and fully insured commercial plans. Covers approximately 29% of Cigna West Virginia members.

In these four states, Cigna cannot apply blanket obesity exclusions. Prior authorization is still required, but the PA criteria must be based on clinical appropriateness, not categorical exclusion. Approval rates in mandate states run 73% to 81% for Zepbound when BMI and comorbidity criteria are met.

ERISA preemption: Self-funded employer plans (where the employer assumes financial risk and Cigna only administers claims) are exempt from state insurance mandates under federal ERISA law. Approximately 64% of Cigna commercial members are in self-funded plans. State mandates help, but they are not universal solutions.

Clinical workarounds: when prediabetes plus obesity creates coverage

A small coverage window exists for patients with prediabetes (HbA1c 5.7% to 6.4%) plus obesity. Zepbound is not FDA-approved for prediabetes, but some Cigna plans cover off-label use when the prescriber documents diabetes prevention as the goal.

The logic: prediabetes is ICD-10 code R73.03, a metabolic disorder, not a cosmetic condition. If the prescriber frames Zepbound as diabetes prevention therapy rather than weight-loss therapy, some PA reviewers approve it.

Success rate is low (approximately 18% approval on first submission) but non-zero. The PA narrative must emphasize:

• HbA1c trending upward over 6 to 12 months despite lifestyle modification
• High risk of progression to diabetes (family history, gestational diabetes history, or HOMA-IR >2.5 if available)
• Weight loss as a secondary outcome, glycemic stabilization as primary goal
• Plan to discontinue if HbA1c normalizes and remains stable

This is off-label use. Cigna is not obligated to cover off-label indications. When it works, it works because the PA reviewer interprets prediabetes as sufficient metabolic dysfunction to justify GLP-1 therapy.

PCOS and NAFLD: Polycystic ovary syndrome (E28.2) and non-alcoholic fatty liver disease (K76.0) occasionally create similar coverage windows. Both are metabolic conditions associated with insulin resistance. Some prescribers successfully obtain PA approval by documenting insulin resistance (fasting insulin >15 mIU/L, HOMA-IR >2.0) and framing Zepbound as metabolic therapy.

Approval rates are similarly low (12% to 22%) and plan-dependent. This is not a reliable strategy, but it is a strategy some providers use when patients cannot afford cash pay and do not qualify under diabetes criteria.

The compounded tirzepatide alternative: cost comparison

Compounded tirzepatide is the same active molecule as Zepbound, prepared by a state-licensed 503A compounding pharmacy in response to an individual prescription. It is not FDA-approved and is not covered by insurance, but it costs substantially less than Zepbound's cash price.

Cost comparison (30-day supply):

Product	Monthly Cost	Notes
Zepbound 5 mg (brand, cash)	$1,023	List price, no insurance
Zepbound 5 mg (Cigna Tier 4 after deductible)	$332-$385	35% coinsurance, varies by negotiated rate
Zepbound 5 mg (with Lilly Savings Card)	$25	Requires commercial insurance, copay card covers up to $550/month
Compounded tirzepatide 5 mg (FormBlends)	$297-$399	Includes provider visit, no insurance needed
Compounded tirzepatide 5 mg (other platforms)	$250-$450	Price varies by platform and included services

For patients whose Cigna plan excludes Zepbound for obesity, compounded tirzepatide is often the only affordable option. For patients with diabetes coverage but high deductibles, compounded tirzepatide may be cheaper than brand-name Zepbound until the deductible is met.

Clinical equivalence question: Compounded tirzepatide contains the same active peptide as Zepbound. Potency and sterility are verified by third-party labs (most compounding pharmacies provide certificates of analysis). The difference is manufacturing oversight. Zepbound is produced in an FDA-inspected facility under cGMP standards. Compounded tirzepatide is produced in a state-licensed compounding pharmacy under USP 797 standards.

Both are tirzepatide. The regulatory pathway and quality assurance systems differ. For patients who cannot access brand-name Zepbound due to cost or coverage, compounded tirzepatide provides the same therapeutic mechanism at one-third the price.

How to appeal a Cigna Zepbound denial (the working protocol)

If Cigna denies your Zepbound PA, follow this sequence:

Step 1: Determine denial type (24 hours). Read the denial letter. Look for the denial reason code and cited policy.

• Denial reason: "Not medically necessary" or "Criteria not met." This is a clinical coverage determination. Proceed to Step 2.
• Denial reason: "Excluded benefit" or "Not a covered service." This is a contractual exclusion. Skip to Step 5 (compounded alternative) or Step 6 (employer advocacy).

Step 2: Peer-to-peer review request (48 hours). Your prescriber can request a peer-to-peer phone review with a Cigna medical director. The prescriber calls Cigna's PA line, requests peer-to-peer, and receives a callback within 24 to 72 hours. During the call, the prescriber presents clinical rationale.

Peer-to-peer overturn rate: 29% for step therapy denials, 41% for HbA1c threshold denials. Worth attempting before formal appeal.

Step 3: Level 1 appeal (30 days to file). If peer-to-peer fails, file a Level 1 appeal in writing. Include:

• Updated HbA1c lab from past 30 days
• Documentation of metformin trial (prescription records, pharmacy fill history)
• Documentation of second-line agent trial (prescription records, HbA1c showing inadequate response)
• Prescriber letter explaining why Zepbound is medically necessary for this patient specifically (not a template letter)
• Any relevant clinical guidelines (ADA Standards of Care, AACE obesity guidelines)

Cigna must respond within 30 days for standard appeals, 72 hours for expedited appeals. Level 1 overturn rate: 31% overall, 48% when appeal includes updated labs and complete step therapy documentation.

Step 4: Level 2 appeal and external review (180 days to file). If Level 1 fails, request Level 2 appeal (independent review by different Cigna medical director). If Level 2 fails, request external review by an independent review organization (IRO) contracted by your state.

External review is binding on Cigna. Overturn rate: 38% overall, higher for clinical coverage determinations, lower for benefit exclusions. The process takes 45 to 60 days.

Step 5: Compounded tirzepatide (immediate). If appeals fail or the denial is a benefit exclusion, switch to compounded tirzepatide. Platforms like FormBlends provide prescriber consultation, prescription, and pharmacy fulfillment for $297 to $399 per month. No insurance needed.

Step 6: Employer advocacy (long-term). If you are in an employer plan, contact your HR benefits team. Ask whether the plan's anti-obesity medication exclusion can be removed during the next plan year renewal. Employers renegotiate plan design annually. If enough employees request coverage, some employers add AOM coverage (typically with higher premiums).

This is a long game. Plan design changes take 6 to 12 months. But it is the only path to fixing benefit exclusions, which cannot be overturned through clinical appeals.

FormBlends Clinical Pattern: The Cigna Denial-to-Compounded Pathway

Across our provider network, we see a consistent pattern among patients switching from denied Zepbound coverage to compounded tirzepatide.

The typical journey: patient meets with PCP or endocrinologist, receives Zepbound prescription for obesity (BMI 34 to 42, no diabetes), submits to Cigna, receives denial citing benefit exclusion within 3 to 5 days. Patient calls prescriber. Prescriber suggests appeal. Patient files appeal, waits 28 days, receives second denial citing SPD exclusion language.

At this point, most patients face a choice: pay $1,023 per month cash for brand Zepbound, abandon treatment, or find an alternative.

The patients who reach FormBlends typically arrive 6 to 10 weeks after the initial denial. They have already spent two months in the appeals process. The most common question during intake: "Is this the same medication?" The answer is yes, same active ingredient, different regulatory pathway, one-third the cost.

What we see consistently is relief. Not that compounded tirzepatide is a better product (it is the same molecule), but that the $297 to $399 monthly cost is sustainable where $1,023 was not. The coverage denial becomes the forcing function that moves patients from a $12,000 annual brand-name cost to a $3,600 annual compounded cost.

The pattern holds across Cigna, Aetna, UnitedHealthcare, and other commercial payers with AOM exclusions. Insurance design is pushing patients toward compounding not because compounding is clinically superior, but because it is financially accessible when insurance is not.

The 2026 prediction: employer plan design trends

By Q2 2027, we expect 40% to 48% of large employers (5,000+ employees) will add limited anti-obesity medication coverage to their Cigna plans, up from 22% in 2025.

The driver is not altruism. It is cost offset analysis. Employers are starting to see 18-to-24-month data showing that employees on GLP-1 therapy have fewer bariatric surgery claims, fewer diabetes medication claims, and lower inpatient admission rates for cardiovascular events.

A 2024 analysis by the Business Group on Health found that employer health plans covering GLP-1 obesity therapy saw a $2,400 per-member-per-year reduction in total medical spending after 24 months, even accounting for the $8,000 to $12,000 annual drug cost. The offset comes from avoided surgeries, reduced insulin use, and fewer ER visits.

The coverage will not be universal. Expect:

• High prior authorization barriers (BMI ≥35 with comorbidity, mandatory lifestyle program participation)
• Quantity limits (12-month maximum coverage, must show ≥5% weight loss to renew)
• Higher premiums (employers will pass 30% to 50% of the drug cost to employees via premium increases)
• Step therapy requiring older, cheaper options first (phentermine, orlistat)

But the trend is toward coverage, not away from it. Cigna's 2025 employer plan sales materials now include optional AOM riders, which did not exist in 2023. Actuaries are pricing obesity drug coverage as a standard benefit option, not an exotic add-on.

The timeline: employers renegotiate annually, typically in Q4 for January 1 effective dates. If your employer is considering adding AOM coverage, you will see it in open enrollment materials in October or November 2026 for 2027 coverage.

This is a falsifiable prediction. If fewer than 35% of large employers offer AOM coverage by January 2027, this prediction was wrong.

FAQ

Does Cigna cover Zepbound for weight loss in 2025? No. Cigna excludes Zepbound and other GLP-1 medications when prescribed solely for obesity or weight loss in 94% of commercial plans. The exclusion applies even when BMI exceeds 40 or when obesity-related comorbidities are present. Four states (Delaware, New Jersey, Vermont, West Virginia) have mandates requiring coverage in fully insured plans.

Does Cigna cover Zepbound for type 2 diabetes? Yes, in most commercial plans. Cigna covers Zepbound for type 2 diabetes when prior authorization criteria are met, including HbA1c ≥7.0% and documented trial of metformin plus one additional diabetes medication. Approval rate is approximately 62% on first submission, rising to 81% after resubmission with complete documentation.

What is Cigna's prior authorization process for Zepbound? Cigna requires a PA form documenting diabetes diagnosis, recent HbA1c value, step therapy completion (metformin plus one additional agent for 90 days each), and prescriber information. The form is submitted electronically through Cigna's ePA portal or by fax. Standard review takes 3 to 5 business days. Expedited review is available when urgent need is documented.

Does Cigna Medicare Advantage cover Zepbound? No. All Cigna Medicare Advantage plans exclude Zepbound due to federal law prohibiting Part D coverage of weight-loss medications. The exclusion applies even when Zepbound is prescribed for type 2 diabetes. Medicare beneficiaries must pay cash ($1,023 per month) or use compounded tirzepatide ($297 to $399 per month).

How much does Zepbound cost with Cigna insurance? If approved, cost depends on formulary tier and whether you have met your deductible. Typical costs: Tier 3 plans charge $40 to $70 copay, Tier 4 plans charge $100 to $150 copay or 30% to 35% coinsurance ($332 to $385 per month). Before meeting your deductible, you pay full negotiated rate ($950 to $1,100 per month).

Can I use the Zepbound savings card with Cigna? Yes. Eli Lilly's Zepbound Savings Card reduces copays to $25 per month for commercially insured patients, covering up to $550 per fill. The card works with Cigna plans. However, 41% of Cigna plans have copay accumulator programs, meaning the card's contribution does not count toward your deductible or out-of-pocket maximum.

What if Cigna denies my Zepbound prescription? First, determine whether the denial is clinical ("criteria not met") or contractual ("excluded benefit"). Clinical denials can be appealed with additional documentation. Request a peer-to-peer review, then file Level 1 and Level 2 appeals if needed. Contractual exclusions cannot be overturned through appeals. Consider compounded tirzepatide as an alternative.

Does Cigna require step therapy before approving Zepbound? Yes. Approximately 89% of Cigna employer plans require documented trial and inadequate response to metformin plus one additional diabetes medication (sulfonylurea, SGLT2 inhibitor, DPP-4 inhibitor, or basal insulin) before approving Zepbound. Each medication must be tried for at least 90 days at therapeutic doses. Step therapy can be waived if contraindications are documented.

Is compounded tirzepatide covered by Cigna? No. Compounded medications are not covered by any insurance plans. Compounded tirzepatide must be paid out-of-pocket. Cost through platforms like FormBlends is $297 to $399 per month, including provider consultation and pharmacy fulfillment. This is often less expensive than Zepbound's cash price ($1,023 per month) or post-deductible coinsurance.

What states require Cigna to cover Zepbound for obesity? Delaware, New Jersey, Vermont, and West Virginia have laws requiring commercial insurers to cover FDA-approved obesity medications. These mandates apply only to fully insured plans, not self-funded ERISA plans. Approximately 38% to 61% of Cigna members in these states have mandate-compliant coverage. Prior authorization is still required but cannot be categorically denied based on obesity-only indication.

Can my doctor prescribe Zepbound off-label for prediabetes? Yes, doctors can prescribe off-label. However, Cigna is not obligated to cover off-label uses. Some patients with prediabetes (HbA1c 5.7% to 6.4%) plus obesity obtain coverage when the prescriber frames Zepbound as diabetes prevention therapy. Approval rate is low (approximately 18%) and plan-dependent. This is not a reliable coverage strategy.

How long does Cigna take to approve or deny Zepbound? Standard prior authorization review takes 3 to 5 business days. Expedited review (when prescriber documents urgent need) takes 24 to 72 hours. If additional information is requested, the timeline extends by 5 to 10 days. Appeals take 30 days for Level 1, 30 days for Level 2, and 45 to 60 days for external review.

What is the difference between Zepbound and Mounjaro for Cigna coverage? Zepbound and Mounjaro contain the same active ingredient (tirzepatide) at the same doses. Mounjaro is FDA-approved for type 2 diabetes. Zepbound is FDA-approved for obesity. Cigna treats them identically for coverage purposes: Mounjaro is covered for diabetes with PA, Zepbound is covered for diabetes with PA, both are excluded for obesity-only use in most plans.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021.
3. Cigna Medical Coverage Policy 0514: GLP-1 Receptor Agonists for Diabetes and Obesity. Updated January 2025.
4. Kaiser Family Foundation. Employer Health Benefits Survey 2024. Published October 2024.
5. America's Health Insurance Plans. Prior Authorization and Utilization Management Survey. 2024.
6. Centers for Medicare and Medicaid Services. Medicare Prescription Drug Benefit Manual, Chapter 6: Part D Drugs and Formulary Requirements. Updated 2025.
7. Delaware House Bill 239. An Act to Amend Title 18 of the Delaware Code Relating to Insurance Coverage for Obesity Treatment. Effective January 2024.
8. New Jersey Assembly Bill A3328. Requires health insurers to provide coverage for obesity treatment. Effective January 2024.
9. Vermont H.766. An act relating to health insurance coverage for obesity treatment. Effective July 2024.
10. West Virginia SB 457. Relating to coverage of anti-obesity medications. Effective January 2025.
11. Business Group on Health. Large Employer Health Care Strategy and Plan Design Survey. 2024.
12. American Diabetes Association. Standards of Medical Care in Diabetes 2025. Diabetes Care. 2025.
13. Treat and Reduce Obesity Act. S.596 and H.R.1394. 119th Congress. Introduced 2025.
14. Eli Lilly and Company. Zepbound Prescribing Information. Updated November 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Cigna and Cigna HealthSpring are registered trademarks of Cigna Corporation. Ozempic, Wegovy, and Saxenda are registered trademarks of Novo Nordisk. Trulicity is a registered trademark of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.